Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...
In a study, IV fosfomycin appeared less effective than IV ceftriaxone or meropenem for bacteremic UTI caused by multidrug-resistant E. coli, but the drug may be considered for selected patients with ...
Patients were randomized to receive cefiderocol intravenously (IV) every 8 hours (n=145) or meropenem IV every 8 hours (n=146) for a period of 7-14 days, in addition to linezolid (to cover methicillin ...
Zerbaxa is noninferior to meropenem for the treatment of adult patients with ventilated nosocomial pneumonia, or VNP, according to phase 3 data from the ASPECT-NP trial presented at the European ...
LAKE FOREST, Ill., June 22 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback